We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 09, 2023

Efficacy and Safety of Avapritinib in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study
Oncologist 2022 Dec 07;[EPub Ahead of Print], J Li, X Zhang, Y Deng, X Wu, Z Zheng, Y Zhou, S Cai, Y Zhang, J Zhang, K Tao, Y Cui, H Cao, K Shen, J Yu, Y Zhou, W Ren, C Qu, W Zhao, J Hu, W Wang, J Yang, L Shen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading